Navigation Links
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

PRINCETON, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, January 13, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

    Contact: Laura S. Choi                   Nichol Ochsner
             Investor Relations              Corporate Communications (media)
             Phone: 609-430-2880, x2216      Phone: 609-430-2880, x2214


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the RBC Capital Markets Healthcare Conference
2. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
3. Medarex Announces 2008 Third Quarter Financial Results
4. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
8. Medarex Announces July 10 Live Webcast of R&D Day Event
9. Medarex to Present at the Jefferies Second Annual Healthcare Conference
10. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
11. Medarex to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... The ... the organization’s history, it is offering its 2016 AAT Member Certification Qualification Course for ... The curriculum for the webinar, which will include a detailed review of hardware, software, ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Vice President for Public Policy for the National Organization for Rare Disorders (NORD). ... groups to ensure their voices are heard throughout the drug regulatory review process. ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
Breaking Biology Technology:
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated ... human interface solutions, today announced sampling of S1423, ... for wearables and small screen applications including smartwatches, ... printers. Supporting round and rectangular shapes, as well ... excellent performance with moisture on screen, while wearing ...
Breaking Biology News(10 mins):